Provided by Tiger Trade Technology Pte. Ltd.

OptimizeRx Corporation

6.15
-0.1600-2.54%
Post-market: 6.10-0.0500-0.81%19:07 EDT
Volume:631.83K
Turnover:3.88M
Market Cap:115.37M
PE:22.78
High:6.49
Open:6.31
Low:6.00
Close:6.31
52wk High:22.25
52wk Low:5.54
Shares:18.76M
Float Shares:14.32M
Volume Ratio:1.44
T/O Rate:4.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2700
EPS(LYR):0.2700
ROE:4.18%
ROA:4.33%
PB:0.90
PE(LYR):22.78

Loading ...

Lake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)

TIPRANKS
·
Mar 02

OptimizeRx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Feb 05

The 13% return this week takes OptimizeRx's (NASDAQ:OPRX) shareholders one-year gains to 156%

Simply Wall St.
·
Jan 08

BRIEF-Optimizerx And Experian Collaborate To Improve Privacy-Safe Identity Resolution In Healthcare Marketing

Reuters
·
Jan 07

OptimizeRx Partners with Experian to Enhance Privacy-Safe Healthcare Marketing

Reuters
·
Jan 07

OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing

THOMSON REUTERS
·
Jan 07

OptimizeRx Chief Finance & Strategy Officer Edward Stelmakh Reports Disposal of Common Shares

Reuters
·
Dec 22, 2025

OptimizeRx Secures Exclusive Multi-Year Partnerships to Expand Point-of-Care Network

Reuters
·
Dec 17, 2025

Halozyme Therapeutics Elects Jim Lang to Board of Directors

Reuters
·
Dec 09, 2025

OPTIMIZERx Q3 Revenue USD 26.1 Million Vs. IBES Estimate USD 23.8 Million

Reuters
·
Nov 20, 2025

OptimizeRx Unveils Presentation Showcasing Technology Solutions for Patient Engagement and Pharma Connectivity

Reuters
·
Nov 19, 2025

Stifel Nicolaus Remains a Buy on OptimizeRx (OPRX)

TIPRANKS
·
Nov 19, 2025

OptimizeRx Is Maintained at Equal-Weight by Stephens & Co.

Dow Jones
·
Nov 17, 2025

OptimizeRx Corporation Files Initial Beneficial Ownership Statement for Brendan W. Merrell, Chief Operating Officer

Reuters
·
Nov 10, 2025

OptimizeRx Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Partnerships and Predictable Revenue Model

Earnings Call
·
Nov 10, 2025

OptimizeRx (OPRX) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 10, 2025

OptimizeRx Down Over 17%, on Pace for Largest Percent Decrease Since November 2024 -- Data Talk

Dow Jones
·
Nov 08, 2025

OptimizeRx Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07, 2025

OptimizeRx reports Q3 revenue of $26.1 million, up 22% year-over-year

Reuters
·
Nov 07, 2025

BRIEF-OPTIMIZERx Q3 Revenue USD 26.1 Million Vs. IBES Estimate USD 23.8 Million

Reuters
·
Nov 07, 2025